28 matches for your search in the start-up spotlight
rss
11-Mar-2025
Sun Pharmaceutical Industries Limited and Checkpoint Therapeutics, Inc. announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing ...
With nearly 1,500 entities, Europe hosts a larger number of cancer-related startups than the US
04-Feb-2025
Cancer remains a major health threat in Europe, which accounts for nearly 25% of global cases and over 20% of deaths, despite having less than 10% of the world's population[1]. Technological advancements are improving survival rates, with European healthcare systems showcasing excellence in ...
Araris to receive an upfront fee and milestone payments potentially totalling USD 780 million plus royalties on net product sales
15-Jan-2025
Araris Biotech AG, a Swiss oncology biotech spin-off company developing next-generation antibody drug conjugates (ADCs), announced they have entered a Research Collaboration and Option to License Agreement (“RCO”) under which Araris will use its proprietary linker-conjugation platform, AraLinQ™, ...
16-Sep-2024
PhoreMost Ltd. announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus ...
Michael Bauer from Novo Holdings and Lucille Conroy from Abingworth will join Myricx Bio Board of Directors
16-Jul-2024
Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), announced the closing of its series A financing raising £90m ($114m). The round was co-led by new leading life science investors Novo Holdings ...
11 start-ups and two relocations show start-up momentum
09-Jul-2024
At this year's BayOConnect conference, BioM presented his latest annual report "Biotech in Bavaria 2023/24 - Incubating Science for Health". With the report, the Biotech Cluster Development Organization presented the current biotech figures as well as developments and successes of the Bavarian ...
Pathios Therapeutics raises $25M in first close of Series B financing to advance first-in-class immunotherapy approach into clinic
23-Apr-2024
Pathios Therapeutics Limited, a biotech company focused on the development of first-in-class therapies for cancer, announced that the company has raised USD $25 million in the first close of a Series B financing. The financing consists of a new strategic investment from Bristol Myers Squibb, as ...
"Together with Bayer, we’re excited to transform AI’s immense potential into a reality for healthcare"
18-Mar-2024
Bayer and Aignostics GmbH announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. Aignostics is a spin-off from one of the world’s leading hospitals, Charité-Universitätsmedizin Berlin, ...
"DISCO is uniquely positioned to transform cancer care"
18-Jan-2024
DISCO Pharmaceuticals ("DISCO"), a specialist biotech unlocking thesurfaceome of cancer cells at scale to identify new targets and develop first in class drugs, emerges from stealth. The Company, operating out of Cologne, Germany and Schlieren, Switzerland, successfully raised seed financing ...
Galapagos to pay up to $27 million in upfront and preclinical milestone payments to BridGene
08-Jan-2024
Galapagos NV announced that it has entered into a strategic collaboration and licensing agreement with BridGene Biosciences, Inc. (“Bridgene”), a biotechnology company that uses proprietary chemoproteomics technology to discover novel small molecule drug candidates. Through this collaboration, ...
